Results 1 to 10 of about 18,714 (151)
Rivaroxaban in Peripheral Artery Disease after Revascularization
New England Journal of Medicine, 2020 BACKGROUND Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.
Marc P Bonaca +2 more
exaly +2 more sources
Lancet, The, 2018 BACKGROUND Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.
Jackie J Bosch +2 more
exaly +2 more sources
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
New England Journal of Medicine, 2019 BACKGROUND Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS In this double‐blind, randomized trial involving high‐risk
Alok A Khorana +2 more
exaly +2 more sources
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
New England Journal of Medicine, 2018 Background Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke ...
Hardi Mundl +2 more
exaly +2 more sources
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
New England Journal of Medicine, 2011 Manesh R Patel +2 more
exaly +3 more sources
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
New England Journal of Medicine, 2017 John W. Eikelboom +2 more
exaly +2 more sources
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
New England Journal of Medicine, 2010 Rupert M Bauersachs +2 more
exaly +2 more sources
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
New England Journal of Medicine, 2012 Eugene Braunwald +2 more
exaly +2 more sources
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
New England Journal of Medicine, 2017 Jeffrey I Weitz +2 more
exaly +2 more sources
Frontiers in Pharmacology, 2021 Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion.
Rui-juan Xu +5 more
doaj +1 more source